Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
NewAmsterdam Pharma 12.12M share Secondary priced at $24.50
The deal size was increased to $416.5M from $300M and priced below last closing price of $25.57. Jefferies, Goldman Sachs, Leerink, TD Cowen,
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH),
NewAmsterdam Pharma (NAMS) Shatters Expectations: Why Its Stock is Soaring Today
NewAmsterdam Pharma (Nasdaq: NAMS) took a commanding leap in the stock market, thanks to the announcement of positive topline data from its Phase 3 BROADWAY clinical trial. This trial evaluated obicetrapib,
Buy Rating on NewAmsterdam Pharma: Promising Phase 3 Results and Increased Price Target
Serge Belanger, an analyst from Needham, maintained the Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report). The associated
14h
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
BioPharma Dive
2d
NewAmsterdam drug shows ‘unexpected’ signs of protecting the heart in latest study
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...
1d
NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts
NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...
2d
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
The Pharma Letter
1d
NewAmsterdam leaps on positive trial results
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...
7d
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma
During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma NAMS, revealing diverse outlooks ...
6d
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Recommendation of “Buy” from Analysts
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has earned an average recommendation of “Buy” from the six research firms ...
Investor's Business Daily on MSN
1d
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Drug
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
2d
NewAmsterdam Pharma Says Main Goal In Phase 3 BROADWAY Study Achieved; Stock Up In Pre-market
NewAmsterdam Pharma Company N.V. (NAMS), a late-stage, clinical biopharmaceutical company, Tuesday announced positive topline data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
NASDAQ
Common stock
Public offering
Pre-Funded Warrants
Feedback